Document:

Document

EXECUTION VERSION

RESTATEMENT AGREEMENT
RESTATEMENT AGREEMENT, dated as of October 30, 2020 (this “Restatement Agreement”), to that certain Loan and Guarantee Agreement, dated as of September 28, 2020 (the “Existing Loan and Guarantee Agreement”, and as amended and restated by this Restatement Agreement, and as may be further amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Loan and Guarantee Agreement”), among ALASKA AIRLINES, INC., a corporation organized under the laws of the State of Alaska (the “Borrower”), ALASKA AIR GROUP, INC., a corporation organized under the laws of the State of Delaware (the “Parent”), the Guarantors party hereto from time to time, the UNITED STATES DEPARTMENT OF THE TREASURY (“Treasury”), as Initial Lender and THE BANK OF NEW YORK MELLON, as Administrative Agent and as Collateral Agent.  Capitalized terms used and not otherwise defined herein shall have the meanings assigned to such terms in the Loan and Guarantee Agreement.

W I T N E S S E T H:
WHEREAS, the Parent, the Borrower, the Guarantors Treasury and the Agents are each party to the Existing Loan and Guarantee Agreement;

 WHEREAS, the Borrower has requested that Treasury extend additional  Commitments to the Borrower (the “Additional Commitments”) as is permissible under the Coronavirus Aid, Relief, and Economic Security Act, Pub. L. 116-136 (Mar. 27, 2020), as the same may be amended form time to time (the “CARES Act”) to the Borrower, and Treasury is willing to do so on the terms and conditions set forth herein; 

WHEREAS, pursuant to Section 4003(h)(1) of the CARES Act, for purposes of the Code, the Loans made pursuant to the Commitments (as increased by the Additional Commitments being provided hereby) shall be treated as indebtedness and as having been issued for their aggregate stated principal amount, and the interest payable pursuant to Section 2.09(a) of the Loan and Guarantee Agreement shall be treated as qualified stated interest;

WHEREAS, Loans made pursuant to the Commitments (as increased by the Additional Commitments being provided hereby) will be secured by Liens on the Collateral securing the existing Obligations, together with Liens on any Additional Collateral, subject to the distribution priorities set forth in the Loan and Guarantee Agreement; 
WHEREAS, pursuant to Section 11.02 of the Loan and Guarantee Agreement, the Borrower has requested amendments to the Existing Loan and Guarantee Agreement as set forth in this Restatement Agreement; and
WHEREAS, Treasury has agreed to amend the Existing Loan and Guarantee Agreement as more particularly set forth in this Restatement Agreement.

NOW, THEREFORE, in consideration of the mutual promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
Section 1.Additional Commitments.  Treasury hereby agrees to provide Additional Commitments to the Borrower on the Restatement Effective Date on the terms set forth herein and in the Loan and Guarantee Agreement and the other Loan Documents, and subject to the conditions set forth below, in an aggregate principal amount, together with the Closing Date Commitment, not to exceed the amount of the Commitments as defined in the Loan and Guarantee Agreement (as amended hereby).  The Additional Commitments shall be deemed to be “Commitments” under and as defined in the Loan and Guarantee Agreement (as amended hereby) for all purposes of the Loan and Guarantee Agreement and the other Loan Documents, and shall be secured by the applicable Liens granted to the Collateral Agent for the benefit of the Secured Parties and entitled to the benefits of the applicable Security Documents.
Section 2.Amendments.  Effective as of the Restatement Effective Date, (a) the Existing Loan and Guarantee Agreement is hereby amended and restated, in its entirety, to be in the form attached as Annex A hereto and (b) all of the other Schedules and Exhibits to the Existing Loan and Guarantee Agreement remain in the forms attached to the Existing Loan and Guarantee Agreement.
Section 3.Representations and Warranties.  The Credit Parties represent and warrant to the Administrative Agent, the Collateral Agent and the Lenders as of the Restatement Effective Date that:
(a)The execution, delivery and performance by each Credit Party of this Restatement Agreement and each other Loan Document to which it is party have been duly authorized by all necessary corporate or other organizational action, and do not and will not (a) contravene the terms of its Organizational Documents, (b) conflict with or result in any breach or contravention of, or the creation of any Lien under, or require any payment to be made under (i) any material Contractual Obligation to which each Credit Party is a party or affecting each Credit Party or the material properties of any Credit Party or (ii) any material order, injunction, writ or decree of any Governmental Authority or any arbitral award to which any Credit Party or its property is subject or (c) violate any Law, except to the extent such violation could not reasonably be expected to have a Material Adverse Effect.
(b)No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, each Credit Party of this Restatement Agreement or any other Loan Document, except for (i) such approvals, consents, exemptions, authorizations, actions or notices that have been duly obtained, taken or made and in full force and effect and (ii) filings and consents contemplated by the Security Documents or Section 5.14 of the Loan and Guarantee Agreement.
(c)This Restatement Agreement has been, and each other Loan Document, when delivered hereunder, will have been, duly executed and delivered by each 
2

Credit Party set forth on the signature pages to this Restatement Agreement. This Restatement Agreement constitutes, and each other Loan Document when so delivered will constitute, the legal, valid and binding obligation of each Credit Party hereto enforceable against such Credit Party in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, receivership, moratorium or other Laws affecting the creditors’ rights generally and by general principles of equity.
(d)No Default exists under the Loan and Guarantee Agreement.
(e)All representations and warranties contained in the Loan and Guarantee Agreement and the other Loan Documents are true and correct in all material respects as of the date hereof, except to the extent that (A) such representations or warranties are qualified by a materiality standard, in which case they are true and correct in all respects, and (B) such representations or warranties expressly relate to an earlier date (in which case such representations and warranties are true and correct in all material respects as of such earlier date).
Section 4.Conditions Precedent to Effectiveness. The effectiveness of this Restatement Agreement and the Additional Commitments provided hereby are subject to the satisfaction (or waiver in accordance with Section 11.02 of the Loan and Guarantee Agreement) of the following conditions (and, in the case of each document specified in this Section to be received by the Initial Lender (and the applicable Agent or Agents), such document shall be in form and substance satisfactory to the Initial Lender and/or the applicable Agent or Agents) (the date on which such conditions are satisfied or waived being the “Restatement Effective Date”) when:
(a)Executed Counterparts.  The Initial Lender and the Agents shall have received from each Credit Party hereto a counterpart of this Restatement Agreement and an Amended and Restated Horizon Aircraft, Engine and Propeller Pledge and Security Agreement, substantially in the form attached hereto as Annex B (such amended and restated agreement, the “Amended and Restated Horizon Pledge and Security Agreement”), each signed on behalf of such Credit Party.  Notwithstanding anything herein to the contrary, delivery of an executed counterpart of a signature page of this Restatement Agreement or the Amended and Restated Horizon Pledge and Security Agreement by telecopy or other electronic means, or confirmation of the execution of this Restatement Agreement and the Amended and Restated Horizon Pledge and Security Agreement on behalf of a party by an email from an authorized signatory of such party shall be effective as delivery of a manually executed counterpart of this Restatement Agreement and the Amended and Restated Horizon Pledge and Security Agreement.
(b)Certificates.  The Initial Lender and any applicable Agent shall have received such customary certificates of resolutions or other action, incumbency certificates and/or other certificates of Responsible Officers of the Credit Parties as the Lenders may require evidencing the identity, authority and capacity of each Responsible Officer thereof authorized to act as a Responsible Officer in connection with the Loan Documents;
3

(c)Organizational Documents.  The Initial Lender shall have received customary resolutions or evidence of corporate authorization, secretary’s certificates and such other documents and certificates (including Organizational Documents and good standing certificates) as the Initial Lender may request relating to the organization, existence and good standing of each Credit Party and any other legal matters relating to the Credit Parties, the Loan Documents or the transactions contemplated thereby.
(d)Opinion of Counsel to Credit Parties.  The Initial Lender and the applicable Agent or Agents shall have received opinions of counsel (including opinions of counsel covering the creation and perfection, or the continuing creation and perfection, of the security interests on Collateral, consistent with the opinions delivered on the Closing Date, and including substantially similar opinions with respect to any Additional Collateral) to the Credit Parties that are acceptable to the Initial Lender, addressed to the Initial Lender and the applicable Agent or Agents and dated as of the Restatement Effective Date, in form and substance satisfactory to the Initial Lender and the applicable Agent (and the Parent hereby instructs such counsel to deliver such opinions to such Persons).
(e)Expenses.  The Borrower shall have paid all reasonable fees, expenses (including the reasonable fees and expenses of legal counsel) and other amounts due to the Initial Lender, the Administrative Agent and the Collateral Agent (to the extent that statements for such expenses shall have been delivered to the Borrower on or prior to the Restatement Effective Date); provided that such expenses payable by the Borrower may be offset against the proceeds of any Loans funded on the Restatement Effective Date.
(f)Officer’s Certificate.  The Initial Lender shall have received a certificate executed by a Responsible Officer of the Parent and the Borrower confirming (i) that the representations and warranties contained in Section 3 of this Restatement Agreement are true and correct on and as of the Restatement Effective Date, (ii) that the information provided in the Loan Application Form submitted by the Borrower was true and correct on and as of the date of delivery thereof, (iii) the satisfaction of Sections 4(j) and (l) herein as of the Restatement Effective Date, (iv) the satisfaction of all other conditions precedent to the Restatement Effective Date described in this Section 4 and (v) that no Default or Event of Default exists or will result from the terms of this Restatement Agreement on the Restatement Effective Date.
(g)Appraisals. The Initial Lender shall have received Appraisals of Additional Collateral satisfactory in form and substance and performed by an Eligible Appraiser dated as of a date no earlier than thirty (30) days prior to the Restatement Effective Date.
(h)Consents and Authorizations.  Each Credit Party shall have obtained all consents and authorizations from Governmental Authorities and all consents of other Persons (including shareholder approvals, if applicable) that are necessary or advisable in connection with this Restatement Agreement, any Loan Document, any of the transactions contemplated hereby or thereby or the continuing operations of the Credit Parties and each of 
4

the foregoing shall be in full force and effect and in form and substance satisfactory to the Initial Lender.
(i)Lien Searches.  The Initial Lender shall have received (i) UCC, Intellectual Property and other applicable lien searches, including tax and judgment liens searches, conducted in the jurisdictions and offices where such liens on material assets of the Credit Parties are required to be filed or recorded, in each case, as of the date that such lien searches were last conducted pursuant to the Loan and Guarantee Agreement and (ii) to the extent any Additional Collateral consists of (x) Aircraft and Engine Assets (as defined in the Pledge and Security Agreements), aircraft registry lien searches conducted with the FAA and the International Registry or (y) Spare Part Assets (as defined in the Pledge and Security Agreements), registry lien searches conducted with the FAA (with reference to each Designated Spare Parts Location set forth on Schedule 2.1 of the Pledge and Security Agreements), in each case, reflecting the absence of Liens on the assets of the Credit Parties, other than Permitted Liens or Liens to be discharged on or prior to the Restatement Effective Date pursuant to documentation satisfactory to the Initial Lender.
(j)Collateral Coverage Ratio.  On the Restatement Effective Date (and after giving pro forma effect to any Borrowings on such date), the Collateral Coverage Ratio shall not be less than 2.0 to 1.0.
(k)Solvency Certificate. The Initial Lender shall have received a certificate of the chief financial officer or treasurer (or other comparable officer) of the Parent certifying that the Borrower and its Subsidiaries (taken as a whole) are, and will be immediately after giving effect to the Restatement Agreement, Solvent.
(l)No Material Adverse Effects.  Since the Closing Date, (i) there has been no event or circumstance that, either individually or in the aggregate, has had or could reasonably be expected to have a Material Adverse Effect and (ii) none of the Credit Parties has made a Disposition (including any sale of Currency) of any assets of the type that would be included in the Collateral other than as would have been permitted under the Loan and Guarantee Agreement.
(m) Audits.  On the Restatement Effective Date, the opinion of the independent public accountants (after giving effect to any reissuance or revision of such opinion) on the most recent audited consolidated financial statements delivered by the Parent pursuant to Section 5.01(a) of the Loan and Guarantee Agreement shall not include a “going concern” qualification under GAAP as in effect on the date of this Restatement Agreement or, if there is a change in the relevant provisions of GAAP thereafter, any like qualification or exception under GAAP after giving effect to such change; and 
(n)Perfection Certificate.  The Initial Lender and the Agents shall have received from each Credit Party hereto an amended and restated Perfection Certificate or supplement thereof, updated to include all Additional Collateral, signed on behalf of such Credit Party.  Notwithstanding anything herein to the contrary, delivery of an executed signature page of an amended and restated Perfection Certificate or supplement thereof by 
5

telecopy or other electronic means, or confirmation of the execution of an amended and restated Perfection Certificate or supplement thereof on behalf of a party by an email from an authorized signatory of such party shall be effective as delivery of a manually executed counterpart of an amended and restated Perfection Certificate or supplement thereof.
(o)Perfection of Liens on Collateral.  On or prior to the Restatement Effective Date, in connection with the execution of the Pledge and Security Agreements, the Perfection Requirement (as defined in the Pledge and Security Agreements) shall have been satisfied and all of the perfection steps thereunder shall have been completed, and copies or evidence, if available, of any relevant filings, recordings and other perfection documentation shall have been provided to the Initial Lender, the Administrative Agent and the Collateral Agent. 
Section 5.Miscellaneous. 
(a)Fees. The Borrower shall pay all fees required to be paid to the Administrative Agent, the Collateral Agent and the Lenders and all expenses (including fees and expenses of counsel) required to be paid to the Administrative Agent, Collateral Agent and the Lenders, in each case as required by and in accordance with the terms of the Loan and Guarantee Agreement, as they are due and payable in connection with this Restatement Agreement.
(b)Continued Effectiveness. Notwithstanding anything contained herein, the terms of this Restatement Agreement shall not constitute a novation or termination of the Existing Loan and Guarantee Agreement or any other Loan Documents and are not intended to and do not serve to effect a novation or termination of the obligations outstanding under the Existing Loan and Guarantee Agreement or instruments guaranteeing or securing the same, which instruments shall remain and continue in full force and effect.
(c)Governing Law; Jurisdiction, Etc. THIS RESTATEMENT AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE FEDERAL LAW OF THE UNITED STATES IF AND TO THE EXTENT SUCH LAW IS APPLICABLE, AND OTHERWISE IN ACCORDANCE WITH THE LAW OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE. 
(d)WAIVER OF JURY TRIAL.  TO THE EXTENT PERMITTED BY APPLICABLE LAW, EACH CREDIT PARTY AND EACH LENDER HEREBY UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY CIVIL LEGAL ACTION OR PROCEEDING RELATING TO THIS AGREEMENT, THE LOAN DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. 
(e)Entire Agreement. This Restatement Agreement, the Loan and Guarantee Agreement and the other Loan Documents constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and 
6

understandings, oral or written, relating to the subject matter hereof. The Borrower and the Agents hereby designate this Restatement Agreement as a Loan Document.
(f)Counterparts.  This Restatement Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Restatement Agreement by facsimile or in electronic (e.g., “pdf” or “tif”) format shall be effective as delivery of a manually executed counterpart of this Agreement.
(g)Electronic Execution.  The words “execution,” “signed,” “signature,” and words of like import in this Restatement Agreement shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any Applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.
(h)Successors and Assigns. When this Restatement Agreement has been executed by the Parent, the Borrower, the Guarantors, the Agents and the Lenders party hereto, this Restatement Agreement shall thereafter be binding upon and inure to the benefit of the parties and their respective successors and assigns, in accordance with the terms of the Loan and Guarantee Agreement.
(i)Severability.  If any provision of this Restatement Agreement or the other Loan Documents is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Restatement Agreement and the other Loan Documents shall not be affected or impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions.  The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
(j)Headings. The headings of this Restatement Agreement are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.
(k)Direction to Agents. The Lenders party hereto hereby authorize and direct the Administrative Agent and the Collateral Agent to execute and deliver this Restatement Agreement. 
(l)Release by Credit Parties. Each Credit Party hereto hereby acknowledges and agrees that it has no actual knowledge of any defenses or claims against any Lender, the Agents, any of their respective Affiliates or any of their respective officers, directors, employees, attorneys, representatives, predecessors, successors or assigns with 
7

respect to the Obligations, and that if such Credit Party now has, or ever did have, any defenses or claims with respect to the Obligations against any Lender, the Agents, any of the respective Affiliates or any of their respective officers, directors, employees, attorneys, representatives, predecessors, successors, or assigns, whether known or unknown, at law or in equity, from the beginning of the world through this date and through the time of effectiveness of this Restatement Agreement, all of them are hereby expressly WAIVED, and the Borrower hereby RELEASES each Lender, each Agent, their respective Affiliates and their respective officers, directors, employees, attorneys, representatives, predecessors, successors and assigns from any liability therefor.
(m) No Liability of Agents.  The Agents assume no responsibility for, and shall be entitled to rely on, without any obligation to ascertain or investigate, the correctness of the recitals and statements contained herein. The Agents shall not be liable or responsible in any manner whatsoever for, or in respect of, the validity or sufficiency of this Restatement Agreement.
Section 6.Reaffirmation.
(a)Each Credit Party hereto hereby consents to the execution, delivery and performance of this Restatement Agreement and agrees that each reference to “the Loan and Guarantee Agreement,” “this Agreement,” “hereunder,” “hereof” or words of like import referring to the Loan and Guarantee Agreement in the Loan Documents shall, on and after the Restatement Effective Date, be deemed to be a reference to the Loan and Guarantee Agreement, as amended and restated by this Restatement Agreement.
(b)Each Credit Party hereto hereby reaffirms all of its respective obligations and liabilities under the Loan Documents to which it is a party, as such obligations and liabilities have been amended by this Restatement Agreement, and acknowledges and agrees that such obligations and liabilities remain in full force and effect.
(c)Each Credit Party hereto hereby irrevocably and unconditionally ratifies each Loan Document to which it is a party (as such Loan Documents are amended to and including the date hereof) and ratifies and reaffirms such Credit Party’s guarantee and grant of liens and security interests under the Security Documents and confirms that the guarantees, liens and security interests granted thereunder continue to secure the Obligations, including, without limitation, any additional Obligations resulting from or incurred pursuant to the Loan and Guarantee Agreement.
Section 7.Post-Closing Matters.
(a)Opinion of Crowe & Dunlevy.  The Initial Lender and the applicable Agent or Agents shall receive all opinions of Crowe & Dunlevy (including opinions covering the creation and perfection, or the continuing creation and perfection, of the security interests on Collateral, consistent with the opinions delivered by Crowe & Dunlevy on the Closing Date, and including substantially similar opinions with respect to any Additional Collateral), aviation counsel to the Credit Parties, that are acceptable to the Initial Lender, 
8

addressed to the Initial Lender and the applicable Agent or Agents and dated no later than two (2) Business Days after the Restatement Effective Date, in form and substance satisfactory to the Initial Lender and the applicable Agent (and the Parent hereby instructs Crowe & Dunlevy to deliver such opinions to such Persons).  Failure to comply with this Section 7(a) shall constitute a Default under the Loan and Guarantee Agreement. 

[Remainder of this page intentionally left blank.]

9

    IN WITNESS WHEREOF, the undersigned have caused this Restatement Agreement to be duly executed by their duly authorized representatives, all as of the day and year first above written.

ALASKA AIRLINES, INC., as Borrower

By:    _______________________
    Name:  
    Title:  

[Signature Page to Restatement Agreement – Alaska Airlines]

ALASKA AIR GROUP, INC., as Parent and Guarantor

By:    _______________________
    Name:  
    Title:  

[Signature Page to Restatement Agreement – Alaska Airlines]

HORIZON AIR INDUSTRIES, INC., as Guarantor

By:    _______________________
    Name:  
    Title:  

[Signature Page to Restatement Agreement – Alaska Airlines]

                        
UNITED STATES DEPARTMENT OF THE TREASURY, as the Initial Lender and a Lender

By:    _______________________
    Name:   
Title:  

    
    
[Signature Page to Restatement Agreement – Alaska Airlines]

        

THE BANK OF NEW YORK MELLON, as Administrative Agent 

By:    _______________________
    Name:   
    Title:  

THE BANK OF NEW YORK MELLON, as Collateral Agent

By:    _______________________
    Name:   
    Title:  

[Signature Page to Restatement Agreement – Alaska Airlines]

        Annex A

Form of Amended and Restated Loan and Guarantee Agreement

        Annex B

Form of Amended and Restated Horizon Pledge and Security AgreementEX-10.1

 Exhibit 10.1 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ZIOPHARM ONCOLOGY, INC. HAS
DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZIOPHARM ONCOLOGY, INC. IF PUBLICLY DISCLOSED. 

PUBLIC HEALTH SERVICE 

Amendment 
 This Agreement
is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for
Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”). 

This Cover Page identifies the Parties to this Agreement: 

The U.S. Department of Health and Human Services, as represented by 

National Cancer Institute 
 an
Institute or Center (hereinafter referred to as the “IC”) of the 
 NIH 

and 
 Ziopharm Oncology, Inc.,

 hereinafter referred to as the “Licensee”, 

having offices at One First Avenue, Parris Building #34, Navy Yard Plaza, Boston, MA 02129, 

created and operating under the laws of Delaware. 

Tax ID No.: 84-1475642 

  

					
	A-362-2020	  		  	
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of L-190-2019/0	  	Draft     Ziopharm Oncology, Inc.	  	November 3, 2020
	Model 10-2015	  	Page 1 of 7	  	

 SECOND AMENDMENT TO
L-190-2019/0 
 This is the second amendment (“Second
Amendment”) of the agreement by and between the IC and Licensee having an effective date of May 28, 2019 and having IC Reference Number
L-190-2019/0 (“Agreement”). This Second Amendment, having IC Reference Number L-190-2019/2 includes, in addition to the amendments made below, 1) a Signature Page, 2) Attachment 1 (Royalty Payment Information), and 3) Appendix A - Patent(s) or Patent Application(s). 

WHEREAS, the IC and the Licensee desire that the Agreement be amended a second time as set forth below in order to bring additional
patent rights within the scope of the Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the
IC and the Licensee, intending to be bound, hereby mutually agree to the following: 
  

	1)	 The cover page’s “Serial Number(s) of Licensed Patent(s) or Patent Application(s)” section of
the Agreement, including the complete list of Licensed Patent(s) or Patent Application(s) in this section, shall be deleted. Appendix A of this Second Amendment is hereby incorporated by reference herein. 

 

	2)	 Appendix A - Patent(s) or Patent Application(s) of the Agreement shall be deleted and replaced with
Appendix A - Patent(s) or Patent Application(s) of this Second Amendment. 

  

	3)	 Section 2.2 of the Agreement shall be deleted and replaced with the following:

 “Additional T Cell Receptor” means an identified human, murine or human-murine hybrid T cell receptor
which immunologically recognizes a tumor-mutated peptide derived from epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), or p53 (also known as TP53 or tumor protein p53) presented by a human leukocyte antigen
(“HLA”) allele group (e.g., HLA-A*02, HLA-A*03) (the peptide and the HLA allele group together,
“Peptide-HLA Complex”). 
  

	4)	 Appendix C – VII of the Agreement shall be deleted and replaced with the following:

 VII.     As used herein, a “[***]” means an Additional T Cell Receptor that
immunologically recognizes a Peptide-HLA Complex that is [***]. 
 As used herein, a
“[***]” means any Additional T Cell Receptor that is [***]. 
 In the event an amendment adds several Additional T Cell
Receptors that [***]. 
 Subject to Paragraph 14.4 of this Agreement, for each Additional T Cell Receptor added by written
amendment, the non-creditable, non-refundable amendment issue royalty shall be as follows for each such Additional T Cell Receptor: 

 

					
	 Type of Additional T Cell Receptor
	  	Royalty amount	 
	 [***] recognizing mutated [***] peptide
	  	$	[***	] 
	 Each [***] recognizing mutated [***] peptide
	  	$	[***	] 
	 [***] recognizing mutated [***] peptide
	  	$	[***	] 
	 [***] recognizing mutated [***] peptide
	  	$	[***	] 
	 Each [***] recognizing mutated [***] peptide
	  	$	[***	] 

  

					
	A-362-2020	  		  	
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of L-190-2019/0	  	Draft     Ziopharm Oncology, Inc.	  	November 3, 2020
	Model 10-2015	  	Page 2 of 7	  	

 In addition, for each Additional T Cell Receptor added by written amendment, Licensee
shall pay the same earned royalty, benchmark royalty and sublicensing royalty rates that are applicable to Licensed Fields of Use 1-3. 

 

	5)	 Section 14.6 of the Agreement shall be deleted and replaced with the following:

 14.6    All Agreement notices required or permitted by this Agreement shall be given
by (i) prepaid, first class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other party at the address designated on the following Signature Page, or to
another address as may be designated in writing by the other party, or (ii) by email to the address designated on the following Signature Page, with receipt confirmed by return email from the recipient. Agreement notices shall be
considered timely if the notices are received on or before the established deadline date or sent on or before the deadline date by email or as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier. Parties should
request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing. 

 

	6)	 Within sixty (60) days of the execution of this Second Amendment, the Licensee shall
pay the IC an amendment issue royalty in the sum of four hundred eleven thousand US Dollars ($411,000.00). Payment options may be found in Attachment 1. The parties agree that the foregoing payment obligation shall be in lieu of the non-creditable, non-refundable amendment issue royalty set forth in Paragraph VII of Appendix C of the Agreement for all Additional T Cell Receptors added
pursuant to this Second Amendment. 

  

	7)	 In the event any provision(s) of the Agreement is/are inconsistent with Attachment 1, such provision(s)
is/are hereby amended to the extent required to avoid such inconsistency and to give effect to the payment information in such Attachment 1. 

  

	8)	 All terms and conditions of the Agreement not herein amended remain binding and in effect.

  

	9)	 The terms and conditions of this Second Amendment shall, at the IC’s sole option, be
considered by the IC to be withdrawn from the Licensee’s consideration and the terms and conditions of this Second Amendment, and the Second Amendment itself, to be null and void,
unless this Second Amendment is executed by the Licensee and a fully executed original is received by the IC within sixty (60) days from the date of the IC’s signature found at the Signature
Page. 

  

	10)	 This Second Amendment is effective upon execution by all parties. 

SIGNATURES BEGIN ON NEXT PAGE 

  

					
	A-362-2020	  		  	
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of L-190-2019/0	  	Draft     Ziopharm Oncology, Inc.	  	November 3, 2020
	Model 10-2015	  	Page 3 of 7	  	

 SECOND AMENDMENT TO
L-190-2019/0 
 SIGNATURE PAGE 

In Witness Whereof, the parties have executed this Second Amendment on the dates set forth below. Any communication or notice to be given shall
be forwarded to the respective addresses listed below. 
 For the IC: 
  

			
	/s/
Richard U. Rodriguez                                    
     	  	  9-21-20                    

	Richard U. Rodriguez, MBA	  	Date
	Associate Director	  	
	Technology Transfer Center, National Cancer Institute	  	

 National Institutes of Health Mailing Address or E-mail Address for Agreement
notices and reports: 
 License Compliance and Administration 

Monitoring & Enforcement 
 Office of Technology Transfer

 National Institutes of Health 
 6011 Executive Boulevard,
Suite 325 
 Rockville, Maryland 20852-3804 U.S.A. 
 E-mail: LicenseNotices_Repor@mail.nih.gov 
 For the Licensee (Upon information and belief, the undersigned
expressly certifies or affirms that the contents of any statements of the Licensee made or referred to in this document are truthful and accurate.): 
  

			
	  /s/ Robert Hadfield                               
                 	  	  9/28/20                    
	Signature of Authorized Official	  	Date

 Name: Robert Hadfield 
 Title:
General Counsel 
  

			
	
I.   Official and Mailing Address for Agreement 
notices:

	  
 Rob
Hadfield                                        
                     

Name
  

General
Counsel                                        
                
 Title

  

					
	A-362-2020	  		  	
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of L-190-2019/0	  	Draft     Ziopharm Oncology, Inc.	  	November 3, 2020
	Model 10-2015	  	Page 4 of 7	  	

	
	 Mailing Address:

	
	 One First Avenue, Parris Building
#34                                         
     

	
	 Navy Yard
Plaza                                        
                                         

	
	 Boston, MA
02129                                        
                                      

	
	
                      
                                         
                                         
     

  

					
	Email Address:	  	[***]	 	                                      
                                         
                     
			
	Phone:	  	[***]	 	                                      
                                         
                     
			
	Fax:	  	[***]	 	                                      
                                         
                     

  

					
	
II. Official and Mailing Address for Financial notices (the 
Licensee’s contact person for royalty payments):

	
	 Eshane
Dupree                                        
                        

Name
  

Accounts
Payable                                        
                   
 Title

 
 Mailing Address:

 
 One First Avenue, Parris Building
#34                          
  

Navy Yard
Plaza                                        
                     
  

Boston, MA
02129                                        
                  
  

                      
                                         
                         

  

					
	Email Address:	  	[***]	 	                                      
                                         
                     
			
	Phone:	  	[***]	 	                                      
                                         
                     
			
	Fax:	  	[***]	 	                                      
                                         
                     

 Any false or misleading statements made, presented, or submitted to the Government, including any relevant
omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes
31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) or imprisonment). 

  

					
	A-362-2020	  		  	
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of L-190-2019/0	  	Draft     Ziopharm Oncology, Inc.	  	November 3, 2020
	Model 10-2015	  	Page 5 of 7	  	

 ATTACHMENT 1 – ROYALTY PAYMENT INFORMATION 

New Payment Options Effective March 2018 

The License Number MUST appear on payments, reports and correspondence. 

[***] 

  

					
	A-362-2020	  		  	
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of L-190-2019/0	  	Draft     Ziopharm Oncology, Inc.	  	November 3, 2020
	Model 10-2015	  	Page 6 of 7	  	

 APPENDIX A – PATENT(S) OR PATENT APPLICATION(S) 

Patent(s) or Patent Application(s): 
 Group A 

[***] 
 Group B 

[***] 
 Group C 

[***] 
 Group D 

[***] 
 Group E 

[***] 
 Group F 

[***] 

  

					
	A-362-2020	  		  	
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of L-190-2019/0	  	Draft     Ziopharm Oncology, Inc.	  	November 3, 2020
	Model 10-2015	  	Page 7 of 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]